Report Predicts More Use of Drug Special Designations in 2013

International Pharmaceutical Regulatory Monitor
A A
U.S. and EU regulators hope to increase the use of special designations, such as fast track, priority review and accelerated approval, to speed access to drugs for noncancer diseases that are rare and/or life-threatening, according to a new Tufts University report.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00